Oxford Spin-Out Just Raised $300M to Fix Undruggable Targets

Jan de Vries · 2026-10-16

OMass Therapeutics, a UK biotech spun out of Oxford, just closed an oversubscribed $300 million (€275 million) Series C round. That's a big number for a company most people outside biotech haven't heard of. But the story here isn't just about the money. It's about what that money says: investors are betting big on a new way to drug targets that have stumped scientists for decades. The round was co-led by Bain Capital Life Sciences, Forbion, and Novo Holdings, with participation from Janus Henderson Investors, SV Health Investors, and Jefferson Life Sciences. All existing investors also joined in, including Syncona, Oxford Science Enterprises, GV, Northpond Ventures, Sanofi Ventures, British Business Bank, and the University of Oxford. That's a heavyweight list, and it tells you something: this isn't a fly-by-night idea. It's a platform that serious people believe in. ### Why This Round Matters OMass isn't your typical drug developer. Founded in 2016, it grew out of Professor Dame Carol Robinson's lab at Oxford, where she pioneered native mass spectrometry. The goal? To translate that research into small molecule therapeutics against targets that have historically been hard to drug. Their proprietary OdyssION platform combines native mass spectrometry, novel biochemistry, and custom chemistry to study drug targets in their native ecosystems. In plain English: they can see how drugs interact with targets in a more realistic environment, with cell-system fidelity and cell-free precision. Ros Deegan, CEO of OMass, put it this way: "This financing comes at an exciting point in OMass' evolution as we advance OMS1620 into the clinic, with our SLC15A4 inhibitor poised to follow. We have demonstrated the ability of our team and approach to discover and deliver a pipeline of first- and best-in-class programmes in endocrinology and immunology into the clinic." That's not just corporate speak. The lead program, OMS1620, is a potential best-in-class MC2 receptor antagonist heading into Phase 2 trials for congenital adrenal hyperplasia (CAH) and ACTH-dependent Cushing's syndrome. These are serious conditions with limited treatment options, and OMS1620 could offer something better. ### The Bigger Picture: European Biotech Is Heating Up OMass' round isn't happening in a vacuum. 2026 has already seen a slew of significant European therapeutics funding rounds. In France, Bionyra Pharma secured $156 million for inflammatory diseases. Denmark's Breye Therapeutics raised $74 million for its oral small-molecule pipeline, also co-led by Novo Holdings. In the UK, Cambridge-based STORM Therapeutics secured $52 million, Microbiotica raised $46 million, Glasgow's Mironid received $43.5 million, and London's Alchemab Therapeutics secured $32 million. Add in the Netherlands' Laigo Bio with an additional $6 million, and you're looking at roughly $409 million in newly reported financing during 2026—rising to $709 million when OMass' round is included. That's a lot of capital flowing into European biotech. And it's not just about the money. It's about validation. When top-tier investors like Bain Capital and Novo Holdings put their weight behind these companies, it sends a signal that Europe can compete on the global stage. ### What's Next for OMass? The proceeds from this round will push OMS1620 through Phase 2 clinical development. If successful, it could be a game-changer for patients with CAH and Cushing's syndrome. The company also has an SLC15A4 inhibitor in the pipeline, targeting immunology. With this funding, OMass has the resources to translate its progress into a portfolio of clinically differentiated medicines. Evan Greif, Principal at Bain Capital Life Sciences, said: "OMass leverages an experienced team and a clear vision for building a leading therapeutics company that translates complex biology into differentiated medicines for patients with significant unmet needs. We see meaningful potential for OMS1620 to improve the treatment for patients with CAH and look forward to partnering with Ros and the team." Max Klement, Partner at Novo Holdings, added: "We are pleased to join a premier investor syndicate supporting OMass as the Company advances its breakthrough programs into the clinic. Each of these candidates has the potential to address substantial unmet patient needs." So what does this mean for the broader startup ecosystem? It's a reminder that deep tech, especially in biotech, can attract massive rounds even in a cautious market. It also shows that spin-outs from universities like Oxford can become serious players. And for anyone watching European innovation, it's another sign that the continent is producing world-class science that investors are willing to back. For now, all eyes are on OMass as it moves its lead program into the clinic. If the science delivers, this $300 million bet could pay off in a big way—for patients and for the European biotech scene.